For sleep, the evidence does not support a confident answer either way. The original rabbit observation was never built into an established mechanism, and no receptor is known.

Has anyone disproved it?

No, and that is part of the problem. The hypothesis has neither been confirmed nor definitively refuted, which is why reviewers describe it as unresolved rather than wrong.

Why is it still sold and studied?

It has a defined structure, a substantial published literature and an open scientific question attached to it. None of that constitutes evidence of an effect.

DSIP (Delta Sleep-Inducing Peptide)

Does DSIP Actually Induce Sleep? What the Evidence Shows

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

The evidence is weak and unresolved. The original 1977 observation in rabbits has not been built into an accepted mechanism, no receptor has been identified through which such an effect could occur, and a 2006 review in the Journal of Neurochemistry characterised the sleep hypothesis as extremely poorly documented.

Key facts

Original observation: Delta EEG in rabbits, 1977
Receptor identified: No
Gene identified: No
Precursor protein: Not characterised
2006 review verdict: 'A still unresolved riddle'
Field opinion: Divided since publication
Approved for sleep: Nowhere

What the original experiment showed

A fraction isolated from the cerebral venous blood of sleeping rabbits, administered into the ventricles of awake rabbits, was reported to increase delta-wave EEG activity. That is a real observation from a real experiment, and it is the entire foundation of the name. It is also a single species, an intraventricular route, and an EEG endpoint rather than a behavioural one.

Why the hypothesis never consolidated

A proposed endogenous signalling peptide normally becomes accepted biology by a recognisable route: the gene is found, the precursor is characterised, the receptor is identified, and the pathway is reconstructed. DSIP has completed none of these steps. Without a receptor there is no mechanism to test, and without a gene there is no way to knock it out and observe what happens — the two experiments that would settle the question are both unavailable.

Research material referenced

DSIP 5mg — third-party HPLC tested

View — £13.99

What the reviewers say

Kovalzon's 2006 review in the Journal of Neurochemistry is titled 'a still unresolved riddle', and describes the sleep hypothesis as extremely poorly documented. The field's own characterisation of DSIP has been divided since publication — described by some as a breakthrough and by others as a dead end — and three decades of subsequent work did not resolve that split.

Why a large literature is not the same as strong evidence

Roughly 519 indexed papers mention DSIP, which sounds substantial. Volume of publication reflects how interesting a question is, not how well it has been answered. A compound can accumulate hundreds of papers precisely because the central claim keeps failing to resolve — each new study a further attempt rather than a further confirmation.

How to read the vendor literature on this

Most commercial writing about DSIP presents the sleep effect as established, usually by restating the name and citing the 1977 paper. That is circular: the name came from the paper, and the paper is a single rabbit study. Anything asserting a demonstrated effect in humans is describing something the primary literature does not contain.

The position this site takes

DSIP is a compound with an interesting history, a clear structure, a real published literature and an unresolved central claim. That is worth describing accurately. It is not a sleep aid, we do not say it treats or improves anything, and its regulatory status is that of an unlicensed compound supplied for laboratory research.

Extended research context

The DSIP (Delta Sleep-Inducing Peptide) deep dive

Deep dive: a name that was a hypothesis, not a finding

In 1977 the Schoenenberger-Monnier group in Basel electrically stimulated the thalamus of a sleeping rabbit, collected blood draining from its brain, isolated a peptide fraction, and reported that administering it into the ventricles of awake rabbits produced delta-wave EEG activity. They named it delta sleep-inducing peptide. By the standards of the time this was careful, imaginative work, and they followed it properly - the 1978 Pflugers Archiv paper reported sequence, synthesis and activity of the synthetic nonapeptide rather than stopping at a suggestive fraction. The problem is not the original research. It is that a name recording a hypothesis has been read ever since as a summary of established pharmacology, and almost nobody checks whether it was earned.

Deep dive: the three things that are missing

A proposed endogenous peptide becomes accepted biology by a recognisable route. The gene is located. The precursor protein is characterised. A receptor is identified, giving a mechanism and a testable target. DSIP has completed none of these in nearly fifty years. The receptor gap is the most disabling - without one there is no mechanism to test, no dose-response to build, no antagonist to design, and no way to establish that an observed effect runs through the proposed pathway at all. The gene gap is the hardest to explain away: modern genomics located MOTS-c inside a short open reading frame nested within the mitochondrial 12S rRNA gene, sequence already annotated as something else. That a peptide described in 1977 still has no identified gene in any genome is a substantive observation, not an accident of effort.

Deep dive: why 519 papers is not 519 confirmations

DSIP has roughly 519 indexed PubMed records - more than Selank's 135 or Semax's 231. Publication volume tracks how interesting a question is, not how well it has been answered. A tractable question generates a burst of work and then stops; a question that resists resolution generates papers indefinitely, each a further attempt rather than a further confirmation. Kovalzon's 2006 review in the Journal of Neurochemistry states the field's own assessment in its title: a still unresolved riddle. Reading any individual DSIP paper without that context invites mistaking activity for consensus.

Research applications

▸Historical study of humoral sleep-factor hypotheses
▸Electroencephalography and delta-wave research methodology
▸Structure-activity work on flexible, acidic short peptides
▸Comparative work on peptides lacking identified receptors
▸Analytical method development for tryptophan-containing peptides

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓No reducing agent needed — the sequence contains no cysteine
✓No methionine oxidation to expect; a +16 Da satellite warrants explanation
✓Protect from prolonged light — the single tryptophan is mildly photosensitive
✓Expect pH-dependent solubility; the peptide is strongly acidic with no basic residue
✓Aliquot to avoid repeated freeze-thaw cycles

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating the name as evidence of the effect

Fix: The name records a 1977 hypothesis from a single rabbit EEG study. It is not a summary of established pharmacology.

✗ Citing the 1977 paper as proof DSIP induces sleep

Fix: It reports delta-wave EEG activity in rabbits after intraventricular administration — a narrower claim than inducing sleep, in one species, by a route that bypasses every normal barrier.

✗ Assuming DSIP is an established endogenous human peptide

Fix: No gene has been identified in any species, no precursor characterised and no receptor found.

✗ Reading 519 papers as 519 confirmations

Fix: Volume reflects an unresolved question attracting sustained attempts, not accumulated confirmation.

✗ Making any sleep claim about supplied material

Fix: The evidence does not support it and a therapeutic claim about research material is what MHRA enforcement targets.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

So does DSIP work?: For sleep, the evidence does not support a confident answer either way. The original rabbit observation was never built into an established mechanism, and no receptor is known.
Has anyone disproved it?: No, and that is part of the problem. The hypothesis has neither been confirmed nor definitively refuted, which is why reviewers describe it as unresolved rather than wrong.
Why is it still sold and studied?: It has a defined structure, a substantial published literature and an open scientific question attached to it. None of that constitutes evidence of an effect.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More DSIP (Delta Sleep-Inducing Peptide) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum